-Frontline The Supreme Court's ruling against Novartis' patent claim for the cancer drug Glivec paves the way for generic drug companies to keep crucial, life-saving drugs affordable to the common people. By V. VENKATESAN IN their 112-page judgment delivered on April 1, Justice Aftab Alam and Justice Ranjana Prakash Desai of the Supreme Court began with a simple proposition: in order to understand what the law really is, it is essential to...
More »SEARCH RESULT
Total Matching Records found : 202
Superior packaging can’t be used to raise prices: High Court to Sanofi SA -Maulik Vyas
-The Economic Times MUMBAI: In a setback to Sanofi SA, the Bombay High Court has dismissed the plea filed by the French pharmaceutical major saying 'superior' packaging cannot be the argument for higher pricing of drugs. The court order also clarified that fixing the prices of drugs in the country will remain in the domain of the National Pharmaceutical Pricing Authority. In its argument, the pharmaceutical company had said it had relied...
More »SC’s Novartis judgement renews focus on accessible medicine
The recent Supreme Court judgment dismissing pharma giant Novartis’ claim for patent protections in India for its award-winning and prohibitively priced anti-leukemia drug Glivec has renewed the focus on accessibly-priced drugs – in particular the failure of the Indian public healthcare system and health policy to ensure affordable drugs for all. Studies show that as much as 70% of health spending in India comes from out-of-pocket payments, with 50-80% of...
More »Patent justice-Sakthivel Selvaraj
-The Hindu Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...
More »No extension to RTE Act’s implementation deadline -Akshaya Mukul
-The Times of India NEW DELHI: HRD ministry has categorically ruled out extension of three-year deadline to states who failed to create the necessary infrastructure to implement the Right to Education (RTE) Act, whose deadline expired on March 31. Acceding to the extension request would have meant amending the RTE Act. But at the end of 61st meeting of the Central Advisory Board on Education (CABE) HRD minister M M Pallam Raju...
More »
